Cargando…

Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio

BACKGROUND: HPeV have been associated with severe disease in young infants. Of the 17 genotypes described, HPeV 1 and 3 have been the most frequently reported. The epidemiology and clinical features associated with different genotypes have not been well defined. We analyzed the prevalence, genotypes...

Descripción completa

Detalles Bibliográficos
Autores principales: Souverbielle, Cristina Tomatis, Wang, Huanyu, Feister, John, Campbell, Jason, Medoro, Alexandra, Mejias, Asuncion, Ramilo, Octavio, Salamon, Douglas, Leber, Amy, Erdem, Guliz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631025/
http://dx.doi.org/10.1093/ofid/ofx163.1857
_version_ 1783269350693666816
author Souverbielle, Cristina Tomatis
Wang, Huanyu
Feister, John
Campbell, Jason
Medoro, Alexandra
Mejias, Asuncion
Ramilo, Octavio
Salamon, Douglas
Leber, Amy
Erdem, Guliz
author_facet Souverbielle, Cristina Tomatis
Wang, Huanyu
Feister, John
Campbell, Jason
Medoro, Alexandra
Mejias, Asuncion
Ramilo, Octavio
Salamon, Douglas
Leber, Amy
Erdem, Guliz
author_sort Souverbielle, Cristina Tomatis
collection PubMed
description BACKGROUND: HPeV have been associated with severe disease in young infants. Of the 17 genotypes described, HPeV 1 and 3 have been the most frequently reported. The epidemiology and clinical features associated with different genotypes have not been well defined. We analyzed the prevalence, genotypes, and clinical manifestations and outcomes of HPeV in infants ≤ 60 days evaluated at Nationwide Children’s Hospital, Columbus, Ohio. METHODS: We retrospectively reviewed EMRs of all infants ≤ 60 days undergoing sepsis evaluation with a positive HPeV PCR from any site between July 2013 and September 2016. All available HPeV CSF, blood, and superficial site specimens were typed by PCR or Sanger sequencing (types assigned per GenBank®). RESULTS: Of 1,265 patients tested, 131 (10%) were positive for HPeV in at least one site, of which 100 had available isolates for genotyping. Median age was 30 days (IQR 19–39), 55% were male. HPeV3 was identified in 87 (87%), HPeV4 in 6, HPeV1 in 5, and HPeV5 and 6 were identified in one infant each. For comparisons we grouped types 1, 4, 5 and 6 into HPeV0 (n = 13). The circulation of HPeV peaked in the months of July to October independent of the type. However, while HPeV0 were identified only in second half of the year, HPeV3 was detected year round. HPeV3 patients had higher temperatures (P < 0.05). There were no significant differences between HPeV3 vs. HPeV0 in age, gender, presenting symptoms, length of stay, PICU admission and CBC. ALT values were higher in HPeV0 patients (P < 0.01). CSF indices were also similar in both groups. Of the positive CSF isolates for HPeV, 43% had no pleocytosis; all CSF isolates typed were HPeV3. HPeV4 was found in blood and superficial sites. HPeV1, 5 and 6 were only found in superficial sites and more commonly with coinfections (enterovirus [EV], rhinovirus, group B streptococcus). There were 4 PICU admissions, 3 of them had HPeV3 and 1 had HPeV1 (patient also had Rhinovirus/EV bronchiolitis). All patients recovered at the time of discharge. CONCLUSION: HPeV was commonly identified in infants ≤ 60 days undergoing sepsis evaluation. HPeV3 was the most common type in this age group. HPeV4 also caused viremia, while other infrequent types were identified with coinfections. DISCLOSURES: O. Ramilo, Abbvie: Board Member, Consulting fee; Regeneron: Board Member, Consulting fee; Janssen: Board Member and Investigator, Consulting fee and Research grant; NIH: Grant Investigator, Research grant; A. Leber, BioFIre Diagnostics: Research Contractor and Scientific Advisor, Research support, Speaker honorarium and Travel expenses
format Online
Article
Text
id pubmed-5631025
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56310252017-11-07 Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio Souverbielle, Cristina Tomatis Wang, Huanyu Feister, John Campbell, Jason Medoro, Alexandra Mejias, Asuncion Ramilo, Octavio Salamon, Douglas Leber, Amy Erdem, Guliz Open Forum Infect Dis Abstracts BACKGROUND: HPeV have been associated with severe disease in young infants. Of the 17 genotypes described, HPeV 1 and 3 have been the most frequently reported. The epidemiology and clinical features associated with different genotypes have not been well defined. We analyzed the prevalence, genotypes, and clinical manifestations and outcomes of HPeV in infants ≤ 60 days evaluated at Nationwide Children’s Hospital, Columbus, Ohio. METHODS: We retrospectively reviewed EMRs of all infants ≤ 60 days undergoing sepsis evaluation with a positive HPeV PCR from any site between July 2013 and September 2016. All available HPeV CSF, blood, and superficial site specimens were typed by PCR or Sanger sequencing (types assigned per GenBank®). RESULTS: Of 1,265 patients tested, 131 (10%) were positive for HPeV in at least one site, of which 100 had available isolates for genotyping. Median age was 30 days (IQR 19–39), 55% were male. HPeV3 was identified in 87 (87%), HPeV4 in 6, HPeV1 in 5, and HPeV5 and 6 were identified in one infant each. For comparisons we grouped types 1, 4, 5 and 6 into HPeV0 (n = 13). The circulation of HPeV peaked in the months of July to October independent of the type. However, while HPeV0 were identified only in second half of the year, HPeV3 was detected year round. HPeV3 patients had higher temperatures (P < 0.05). There were no significant differences between HPeV3 vs. HPeV0 in age, gender, presenting symptoms, length of stay, PICU admission and CBC. ALT values were higher in HPeV0 patients (P < 0.01). CSF indices were also similar in both groups. Of the positive CSF isolates for HPeV, 43% had no pleocytosis; all CSF isolates typed were HPeV3. HPeV4 was found in blood and superficial sites. HPeV1, 5 and 6 were only found in superficial sites and more commonly with coinfections (enterovirus [EV], rhinovirus, group B streptococcus). There were 4 PICU admissions, 3 of them had HPeV3 and 1 had HPeV1 (patient also had Rhinovirus/EV bronchiolitis). All patients recovered at the time of discharge. CONCLUSION: HPeV was commonly identified in infants ≤ 60 days undergoing sepsis evaluation. HPeV3 was the most common type in this age group. HPeV4 also caused viremia, while other infrequent types were identified with coinfections. DISCLOSURES: O. Ramilo, Abbvie: Board Member, Consulting fee; Regeneron: Board Member, Consulting fee; Janssen: Board Member and Investigator, Consulting fee and Research grant; NIH: Grant Investigator, Research grant; A. Leber, BioFIre Diagnostics: Research Contractor and Scientific Advisor, Research support, Speaker honorarium and Travel expenses Oxford University Press 2017-10-04 /pmc/articles/PMC5631025/ http://dx.doi.org/10.1093/ofid/ofx163.1857 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Souverbielle, Cristina Tomatis
Wang, Huanyu
Feister, John
Campbell, Jason
Medoro, Alexandra
Mejias, Asuncion
Ramilo, Octavio
Salamon, Douglas
Leber, Amy
Erdem, Guliz
Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio
title Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio
title_full Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio
title_fullStr Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio
title_full_unstemmed Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio
title_short Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio
title_sort prevalence, genotypes, clinical manifestations and outcomes associated with human parechovirus (hpev) infections in infants up to 2 months old in central ohio
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631025/
http://dx.doi.org/10.1093/ofid/ofx163.1857
work_keys_str_mv AT souverbiellecristinatomatis prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT wanghuanyu prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT feisterjohn prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT campbelljason prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT medoroalexandra prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT mejiasasuncion prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT ramilooctavio prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT salamondouglas prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT leberamy prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio
AT erdemguliz prevalencegenotypesclinicalmanifestationsandoutcomesassociatedwithhumanparechovirushpevinfectionsininfantsupto2monthsoldincentralohio